Fund+

Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company focuses on developing internal drug discovery programs centered on G-protein coupled receptors (GPCRs), which are critical targets for therapeutic intervention. Utilizing its proprietary CONFO technology, Confo Therapeutics stabilizes active-state conformations of GPCRs, enabling researchers to access previously unreachable structural features. This innovation facilitates the discovery of novel agonists, addressing unmet medical needs and potentially leading to improved treatments in the medical field. The company aims to build a robust portfolio of drug discovery programs, leveraging its unique approach to enhance therapeutic options.

eTheRNA immunotherapies NV specializes in the development of mRNA-based immunotherapies that harness the key role of dendritic cells in the immune system. The company focuses on treating melanoma, triple-negative breast cancer, and infectious diseases through its innovative TriMix technology, which enhances the immune response. Founded in 2013 and headquartered in Niel, Belgium, eTheRNA collaborates strategically with China Grand Pharmaceutical and Healthcare Holdings Limited to advance its research and development efforts. The company aims to lead in nucleic acid-based medicine, enabling partners to create new therapeutic options and improve patient outcomes.

EyeD Pharma SA is a pharmaceutical company based in Liège, Belgium, specializing in the development and commercialization of innovative drug products for ophthalmology. The company focuses primarily on the treatment of glaucoma, a condition traditionally managed through daily eye drop administration. EyeD Pharma aims to enhance the quality of life for patients by creating therapies that reduce side effects associated with existing treatments. In collaboration with ophthalmologists, the company offers new treatment options and surgical products, helping to improve clinical practices and provide therapeutic assistance that is currently lacking in the market.

ExeVir Bio BV, founded in 2020 and based in Zwijnaarde, Belgium, specializes in developing single-domain antibody-based therapies aimed at combating viral infections. The company leverages a llama-derived antibody technology platform to create robust antiviral treatments that offer broad protection against coronaviruses. Notably, it is developing VHH72-FC, an antibody that targets a highly conserved region on the spikes of SARS-CoV-2, crucial for the virus's entry into human cells. ExeVir Bio's rapid response platform for antivirals allows for an agile approach to emerging health threats, enabling the swift generation of drug candidates. The therapeutics produced through this innovative technology are designed to be stable, cost-effective, and accessible on a global scale.

eTheRNA immunotherapies NV specializes in the development of mRNA-based immunotherapies that harness the key role of dendritic cells in the immune system. The company focuses on treating melanoma, triple-negative breast cancer, and infectious diseases through its innovative TriMix technology, which enhances the immune response. Founded in 2013 and headquartered in Niel, Belgium, eTheRNA collaborates strategically with China Grand Pharmaceutical and Healthcare Holdings Limited to advance its research and development efforts. The company aims to lead in nucleic acid-based medicine, enabling partners to create new therapeutic options and improve patient outcomes.

EyeD Pharma SA is a pharmaceutical company based in Liège, Belgium, specializing in the development and commercialization of innovative drug products for ophthalmology. The company focuses primarily on the treatment of glaucoma, a condition traditionally managed through daily eye drop administration. EyeD Pharma aims to enhance the quality of life for patients by creating therapies that reduce side effects associated with existing treatments. In collaboration with ophthalmologists, the company offers new treatment options and surgical products, helping to improve clinical practices and provide therapeutic assistance that is currently lacking in the market.

Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company focuses on developing internal drug discovery programs centered on G-protein coupled receptors (GPCRs), which are critical targets for therapeutic intervention. Utilizing its proprietary CONFO technology, Confo Therapeutics stabilizes active-state conformations of GPCRs, enabling researchers to access previously unreachable structural features. This innovation facilitates the discovery of novel agonists, addressing unmet medical needs and potentially leading to improved treatments in the medical field. The company aims to build a robust portfolio of drug discovery programs, leveraging its unique approach to enhance therapeutic options.

Aelin Therapeutics, a privately held Belgian biotherapeutics company.Aelin Therapeutics is founded by VIB and its partner universities KU Leuven, VUB and UGent, based on the groundbreaking work of renowned structural biologists Prof Joost Schymkowitz and Prof Frederic Rousseau. The company is based on a very comprehensive preclinical Proof of Concept data package illustrating different applications of the technology such as in bacteria and cancer cells, but also in fungi, viruses and plant cells, with publications in high impact journals including Science. The Pept-in technology allows for the rational design of novel biotherapeutics and differentiates itself from any other therapeutic modality through its unique mode of action, its designability and intracellular target space out of reach for typical small molecule or antibody approaches.

Iteos Therapeutics S.A. is a biotechnology company focused on developing immuno-oncology therapeutics to treat cancer patients. Headquartered in Gosselies, Belgium, the company was established in 2011 and operates as a subsidiary of Iteos Therapeutics, Inc. Its product pipeline features EOS-850, a small molecule antagonist targeting the adenosine A2a receptor, currently undergoing open-label Phase 1/2a clinical trials in adult patients. Another key candidate is EOS-448, an anti-TIGIT antibody, also in Phase 1/2a clinical trials. Iteos Therapeutics aims to address immune suppression in the tumor microenvironment by creating small molecule immunomodulators, thereby enhancing the effectiveness of existing cancer treatments and newer immunomodulatory therapies. The company leverages expertise from the Ludwig Cancer Research Institute in its efforts to advance cancer therapies.